Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Equities research analysts at Oppenheimer boosted their FY2025 earnings estimates for Aptose Biosciences in a note issued to investors on Monday, May 9th. Oppenheimer analyst M. Biegler now anticipates that the biotechnology company will post earnings of $0.38 per share for the year, up from their prior forecast of $0.34.
Aptose Biosciences (TSE:APS – Get Rating) (NASDAQ:APTO) last announced its quarterly earnings results on Tuesday, March 22nd. The biotechnology company reported C($0.34) EPS for the quarter, missing the consensus estimate of C($0.23) by C($0.11).
TSE:APS opened at C$1.38 on Wednesday. The firm has a 50-day simple moving average of C$1.53 and a 200-day simple moving average of C$1.92. Aptose Biosciences has a one year low of C$1.30 and a one year high of C$6.98. The firm has a market cap of C$127.28 million and a P/E ratio of -1.46. The company has a debt-to-equity ratio of 0.77, a quick ratio of 9.68 and a current ratio of 10.00.
Aptose Biosciences Company Profile (Get Rating)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.